[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
A new anticancer therapy using tegafur encapsulated in slow-releasing granules (SF-SP) was orally administered at a dose of 1000 mg/day to 38 patients with cancer of the digestive organs. Twenty-eight of these patients were evaluable for response using the criteria of Saito and Koyama's clinical evaluation. Six of 28 patients showed effective response (21.4%). An effective response was observed in of 15 patients with gastric cancer (26.7%). Side-effects from this therapy were encountered in 14 patients (36.8%). An effective response was therefore demonstrated in patients with cancer of the digestive organs.